Kemp Dolliver
Stock Analyst at Brookline Capital
(0.63)
# 4,120
Out of 5,154 analysts
19
Total ratings
38.46%
Success rate
-14.84%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LSTA Lisata Therapeutics | Downgrades: Hold | n/a | $4.18 | - | 2 | Jan 21, 2026 | |
| RNTX Rein Therapeutics | Downgrades: Hold | n/a | $1.22 | - | 2 | Jan 21, 2026 | |
| VRCA Verrica Pharmaceuticals | Upgrades: Buy | $17 | $5.31 | +220.15% | 3 | Dec 18, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $4.99 | +260.72% | 1 | Jul 21, 2025 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $2.61 | +37.93% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $1.53 | +2,252.94% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $0.41 | +7,484.54% | 1 | Jan 25, 2024 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $72.56 | +37.82% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $6.52 | +774.23% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $2.71 | +822.51% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $6.85 | +173.72% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.80 | +900.00% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.63 | +796.83% | 1 | Feb 2, 2022 |
Lisata Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $4.18
Upside: -
Rein Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $1.22
Upside: -
Verrica Pharmaceuticals
Dec 18, 2025
Upgrades: Buy
Price Target: $17
Current: $5.31
Upside: +220.15%
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $4.99
Upside: +260.72%
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $2.61
Upside: +37.93%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $1.53
Upside: +2,252.94%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $0.41
Upside: +7,484.54%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $72.56
Upside: +37.82%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $6.52
Upside: +774.23%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.71
Upside: +822.51%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $6.85
Upside: +173.72%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.80
Upside: +900.00%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.63
Upside: +796.83%